Literature DB >> 29152735

6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain.

Giulia Albertini1, Laura Walrave1, Thomas Demuyser1, Ann Massie2, Dimitri De Bundel1, Ilse Smolders1.   

Abstract

OBJECTIVE: Besides seizures, patients with epilepsy are affected by a variety of cognitive and psychiatric comorbidities that further impair their quality of life. The present study provides an in-depth characterization of the behavioral alterations induced by 6 Hz corneal kindling. Furthermore, we correlate these behavioral changes to alterations in c-Fos protein expression throughout the brain following kindling.
METHODS: Adolescent male Naval Medical Research Institute (NMRI) mice were kindled via repetitive subconvulsive 6 Hz corneal stimulations until they reached the fully kindled state (defined as 10 consecutive generalized seizures). Afterwards we performed an elaborate battery of behavioral tests and we evaluated c-Fos expression throughout the brain using immunohistochemistry.
RESULTS: Fully kindled mice display an abnormal behavioral phenotype, characterized by basal and amphetamine-induced hyperlocomotion, anhedonia, social withdrawal, and deficits in short- and long-term memory. Moreover, 6 Hz corneal kindling enhances c-Fos immunoreactivity in the visual, parahippocampal, and motor cortices and the limbic system, whereas c-Fos+ cells are decreased in the orbital cortex of fully kindled mice. SIGNIFICANCE: The behavioral outcomes of 6 Hz corneal kindling cluster into 3 main categories: positive symptoms, negative symptoms, and cognitive impairment. These symptoms are accompanied by c-Fos activation in relevant brain regions once the fully kindled state is established. Based on the face validity of this model, we speculate that 6 Hz corneal kindling can be used to model not only pharmacoresistant limbic seizures, but also several neurobehavioral comorbidities that affect patients with epilepsy. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  behavior; c-Fos immunoreactivity; corneal kindling; epilepsy; neurobehavioral comorbidities

Mesh:

Substances:

Year:  2017        PMID: 29152735     DOI: 10.1111/epi.13943

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

2.  How do we choose the appropriate animal model for antiseizure therapy development?

Authors:  Melissa Barker-Haliski
Journal:  Expert Opin Drug Discov       Date:  2019-06-28       Impact factor: 6.098

3.  Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Authors:  Carine Bécamel; Dimitri De Bundel; Błażej D Pędzich; Sarah Rubens; Mehdi Sekssaoui; Anouk Pierre; Andries Van Schuerbeek; Philippe Marin; Joel Bockaert; Emmanuel Valjent
Journal:  Neuropsychopharmacology       Date:  2022-04-21       Impact factor: 8.294

Review 4.  Can Old Animals Reveal New Targets? The Aging and Degenerating Brain as a New Precision Medicine Opportunity for Epilepsy.

Authors:  Aaron Del Pozo; Leanne Lehmann; Kevin M Knox; Melissa Barker-Haliski
Journal:  Front Neurol       Date:  2022-04-28       Impact factor: 4.086

5.  Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.

Authors:  Zachery Koneval; Kevin M Knox; Ali Memon; Dannielle K Zierath; H Steve White; Melissa Barker-Haliski
Journal:  Epilepsia       Date:  2020-08-05       Impact factor: 5.864

6.  Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition.

Authors:  Megan Beckman; Kevin Knox; Zachery Koneval; Carole Smith; Suman Jayadev; Melissa Barker-Haliski
Journal:  Neurobiol Dis       Date:  2019-12-17       Impact factor: 5.996

7.  Repeated Administration of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) Attenuates the Chronic Inflammatory Response to Experimental Stroke.

Authors:  Danielle A Becktel; Jacob C Zbesko; Jennifer B Frye; Amanda G Chung; Megan Hayes; Kylie Calderon; Jeffrey W Grover; Anna Li; Frankie G Garcia; Marco A Tavera-Garcia; Rick G Schnellmann; Hsin-Jung Joyce Wu; Thuy-Vi V Nguyen; Kristian P Doyle
Journal:  J Neurosci       Date:  2021-11-24       Impact factor: 6.709

8.  A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task Force.

Authors:  Melissa Barker-Haliski; Lauren C Harte-Hargrove; Teresa Ravizza; Ilse Smolders; Bo Xiao; Claudia Brandt; Wolfgang Löscher
Journal:  Epilepsia Open       Date:  2018-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.